[Actovegin in the treatment of brain injuries of mild and moderate severity]
Abstract:
Sixty-eight patients, including 32 patients of the main group who received aktovegin in addition to standard therapy and 36 patients of the control group with standard therapy only, have been studied. In both groups, various traumatic injuries (small focal injuries, subdural and epidural hematomas, traumatic subarachnoid hemorrhages, a combination of covering hematoma and small focal injuries) have been found. Aktovegin has been used in drops in dosage 400 mg per 200 ml physiological solution for 10 days. A comparative analysis of clinical data and results of instrumental studies (EEG, CT etc) in the main and control groups gives grounds to conclude that the use of aktovegin in the complex with standard therapy improves the course of brain injuries thus promoting the earlier compensation of disturbed functions and shortening the terms of treatment. The regress of asthenic symptoms as well as positive EEG changes are most pronounced.
More Related Videos
09:29Controlled Cortical Impact Model of Mouse Brain Injury with Therapeutic Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Cells
Published on: July 10, 2019
06:50A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
Published on: June 10, 2020
Related Concept Videos
Traumatic Brain Injury l: Introduction
Cerebral Edema ll: Pathophysiology
Secondary Spinal Cord Injury llI: Pathophysiology
Cerebral Edema l: Introduction
Spinal Cord Injury ll: Pathophysiology
Alzheimer's Disease: Treatment
